ewsba.se
EyePoint expects phase III wet AMD top-line data beginning mid-year (LUGANO “this summer” with LUCIA to follow), pursuing a non-inferiority pathway versus on‑label 2 mg aflibercept while targeting six‑month redosing and durability; the trials have had two positive DSMC reviews and a low ~5% discontinuation rate.
The phase III DME program (COMO and CAPRI) is rapidly enrolling with >1/3 of patients enrolled and full enrollment targeted in Q3 2026, with top-line data expected in H2 2027, and the company highlights vorolanib’s multi‑mechanism profile (VEGF, PDGF, and JAK1/IL‑6 signaling) as a potential differentiator for reduced treatment burden.
Financially, Eyepoint ended Q1 with $223 million in cash and investments and reported a net loss of $85 million ($0.99/share) as operating expenses rose to $88 million, and management says current cash should fund operations into Q4 2027, past the wet AMD milestones.
Interested in Eyepoint Pharmaceuticals, Inc.? Here are five stocks we like better.
Breakout Momentum Plays You May Not Know About
EyePoint Pharmaceuticals (NASDAQ:EYPT) executives told investors the company is approaching what they described as a “pivotal inflection point” for its lead program, DURAVYU, with phase III wet age-related macular degeneration (wet AMD) top-line data expected beginning mid-year and a rapidly enrolling phase III program in diabetic macular edema (DME).
President and CEO Dr. Jay Duker said the company remains on track to report phase III top-line data from its wet AMD program, with results from the LUGANO trial expected “this summer” and the second trial, LUCIA, “to follow shortly thereafter.” Duker said EyePoint believes it could “potentially be the first to market among all current investigational sustained release programs.”
→ 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries
Duker reiterated that EyePoint’s phase III wet AMD program is built on a non-inferiority regulatory pathway and compares DURAVYU to on-label 2 mg aflibercept. He said both pivotal trials also evaluate six-month redosing and “statistical superiority in treatment burden reduction” aimed at supporting a label focused on durability.
On trial progress and safety monitoring, Duker said all patients in LUGANO and LUCIA have reached the week 32 visit, when patients in the DURAVYU arms received a second dose. He added that more than 35% of patients have received their third planned dose at week 56. The company has received “two consecutive positive recommendations” from the Independent Data and Safety Monitoring Committee, with a third review scheduled for later in the month.
→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches
Duker also pointed to a low discontinuation rate in the wet AMD phase III program. “Our low discontinuation rate of about 5% remains well below the 10% yearly average typical for wet AMD trials,” he said, adding that none of the discontinuations were related to treatment.
Duker emphasized the company’s view that DURAVYU’s active ingredient, vorolanib, could be differentiated by a multi-mechanism approach. In prepared remarks, he said vorolanib blocks all VEGF isoforms and PDGF at the receptor level, and that preclinical data supports an ability to inhibit IL-6 signaling via the JAK1 receptor.
→ Tyson Foods' Total Returns: Tasty Treats for Income Investors?
EyePoint also discussed data it presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting. Duker said a primary kinase screen and IC50 testing identified vorolanib as “a potent inhibitor of JAK1,” and said the compound inhibited IL-6 leakage in an in vitro model. Later in the call, he described an additional preclinical model involving leakage induced by VEGF and IL-6, saying vorolanib suppressed inflammation in a manner comparable to “an anti-VEGF and an anti-IL-6.”
EyePoint said its phase III DME program is advancing quickly. Duker said enrollment is “rapidly progressing” and the company is targeting full enrollment in both pivotal DME trials in the third quarter of 2026. He noted both DME studies (COMO and CAPRI) are underway, with “over one-third of patients enrolled across both trials” following first patient dosing at the end of February. Top-line data is expected in the second half of 2027.
Chief Medical Officer Dr. Ramiro Ribeiro attributed the pace in part to reusing infrastructure from the wet AMD program, including clinical sites and vendors. He said investigators have described the DME trials as “very patient-centric” and focused on reducing treatment burden, adding that patients are “very excited for a therapy that can last for about six months.” Ribeiro also said the need may be even greater in DME because patients tend to be younger and working, making fewer visits particularly valuable.
Duker added that EyePoint invited 90 wet AMD investigators to participate in the DME trials, and “all 90 accepted,” which he said reflects enthusiasm for DURAVYU.
Discussing endpoints, Duker said EyePoint cannot directly measure IL-6 or JAK1 effects in patients, but is assessing indirect effects. He highlighted secondary endpoints in COMO and CAPRI including visual acuity and OCT at week four, reflecting observations the company cited from its phase II VERONA study. Duker also mentioned fluorescein angiography leakage as another secondary measure, noting that in VERONA, leakage reduction was significant and dose-dependent, and he suggested that greater leakage reduction versus aflibercept would support an inflammation-related mechanism.
Several analysts asked about rescue or supplementation injections. Duker said supplementation in the wet AMD phase III trials will be handled statistically with sensitivity analyses as part of a potential NDA submission and emphasized that the FDA considers the “totality of the data.”
Ribeiro said EyePoint does not review aggregated supplementation injection rates and does not disclose that data publicly. Responding to a question about whether the company can see blinded rescue rates, Ribeiro said only a small internal team reviews supplementation injections to ensure sites follow protocol.
Duker added that EyePoint expects supplementation rates in phase III to be lower than in phase II, citing “tightening of the supplement criteria,” removing physician discretion, redosing at six months, and enrolling a majority of treatment-naïve patients.
Duker said EyePoint continues to invest in launch readiness while remaining “disciplined” with spending. He noted the addition of Chief Commercial Officer Mike Campbell and said the company has expanded capabilities in areas including marketing, market access, regulatory, compliance, and medical affairs.
He also discussed manufacturing readiness, saying EyePoint’s cGMP facility in Northbridge, Massachusetts, has been online for more than a year and is intended to support an anticipated CMC submission for a potential NDA and commercial supply if approved. Duker said the company is preparing for a pre-approval inspection.
On competition, Duker responded to questions about other long-acting TKIs and longer-acting anti-VEGF biologics. He said there is “room for two competitors” in a large market and argued that multiple entries with a new mechanism can help drive physician awareness. On existing long-acting anti-VEGFs, Campbell cited American Society of Retina Specialists survey results, saying the “number one need” in wet AMD treatment remains durability.
Executive Vice President and CFO George Elston said EyePoint ended the first quarter with $223 million in cash and investments. Total net revenue was $0.7 million for the three months ended March 31, 2026, compared with $24.5 million in the prior-year period. Elston said the decrease was primarily due to the recognition of remaining deferred revenue related to a second-quarter 2023 agreement for the license of YUTIQ product rights.
Operating expenses rose to $88 million from $73 million a year earlier, which Elston attributed primarily to phase III trials for DURAVYU in wet AMD and DME and the scale-up of the Northbridge manufacturing facility. Net non-operating income was $2 million. Net loss was $85 million, or $0.99 per share, compared with a net loss of $45 million, or $0.65 per share, in the prior-year quarter.
Elston said cash, cash equivalents, and investments in marketable securities totaled $223 million as of March 31, 2026, down from $306 million at Dec. 31, 2025. He said the company expects its current cash position to fund operations into the fourth quarter of 2027, “beyond key milestones for the phase III wet AMD program expected later this year.”
In closing remarks, Duker said the company remains focused on preparing for the wet AMD phase III top-line data readout expected mid-year and completing enrollment in the phase III DME program in the third quarter of 2026.
Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.
Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.
The article "Eyepoint Pharmaceuticals Q1 Earnings Call Highlights" was originally published by MarketBeat.